4BASEBIO UK SOCIETAS (4BB.L)
4basebio plc engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. It provides AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. The company offers access to its targeted non-viral delivery platform, Hermes. It serves biotech, pharma, and contract development and manufacturing organization. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio plc in July 2021. 4basebio plc was founded in 2008 and is based in Cambridge, the United Kingdom.
Company Info
Highlights
£174.06M
-£0.78
£328.00K
£236.00K
-£5.47M
£1,090.00 - £1,820.00
£1,700.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in 4BASEBIO UK SOCIETAS, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
4BASEBIO UK SOCIETAS (4BB.L) returned -7.02% year-to-date (YTD) and -1.75% over the past 12 months.
4BB.L
-7.02%
-2.17%
-11.76%
-1.75%
N/A
N/A
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of 4BB.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.83% | -3.33% | -2.59% | -0.44% | 0.00% | -7.02% | |||||||
| 2024 | -1.47% | 21.64% | 17.79% | 11.46% | 30.84% | 10.00% | -4.55% | 0.00% | -5.44% | -7.91% | 1.56% | -6.92% | 77.94% |
| 2023 | 3.52% | -2.72% | -8.39% | -2.29% | -11.72% | 1.77% | -2.61% | 9.82% | -9.35% | -7.62% | 9.71% | 20.35% | -4.23% |
| 2022 | -8.94% | -1.79% | -5.45% | 5.77% | -14.55% | -9.57% | 32.35% | 4.44% | -4.26% | -2.22% | 27.27% | 1.43% | 15.45% |
| 2021 | 11.11% | -10.67% | 7.46% | 6.25% | 19.48% | 9.41% | 44.00% | 5.56% | -6.58% | -9.15% | -4.65% | 82.22% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 4BB.L is 46, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for 4BASEBIO UK SOCIETAS (4BB.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the 4BASEBIO UK SOCIETAS. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the 4BASEBIO UK SOCIETAS was 47.71%, occurring on Jul 13, 2022. Recovery took 410 trading sessions.
The current 4BASEBIO UK SOCIETAS drawdown is 38.19%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -47.71% | Sep 30, 2021 | 196 | Jul 13, 2022 | 410 | Feb 27, 2024 | 606 |
| -38.74% | Jun 19, 2024 | 196 | Mar 25, 2025 | — | — | — |
| -31.11% | Feb 22, 2021 | 15 | Mar 12, 2021 | 71 | Jun 25, 2021 | 86 |
| -9.72% | Sep 2, 2021 | 10 | Sep 15, 2021 | 10 | Sep 29, 2021 | 20 |
| -9.44% | Aug 10, 2021 | 6 | Aug 17, 2021 | 9 | Aug 31, 2021 | 15 |
Volatility
Volatility Chart
The current 4BASEBIO UK SOCIETAS volatility is 5.32%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of 4BASEBIO UK SOCIETAS over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of 4BASEBIO UK SOCIETAS, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how 4BASEBIO UK SOCIETAS is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 4BB.L relative to other companies in the Biotechnology industry. Currently, 4BB.L has a P/S ratio of 292.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 4BB.L in comparison with other companies in the Biotechnology industry. Currently, 4BB.L has a P/B value of 8.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |